Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US10138249B2 · kind B2 · utility
15Cited by
15References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2017 |
| Grant date | Nov 27, 2018 |
| Priority date | — |
| Expiry date | Aug 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.